Luo, H., Zhang, L., Yang, B., et al. (2020) A Randomized Phase 2 Trial of Apatinib vs Observation as Maintenance Treatment Following First-Line Induction Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Investigational New Drugs, 38, 148-159.
https://doi.org/10.1007/s10637-019-00828-x

has been cited by the following article:

• TITLE: Research Progress of Anti-Angiogenic Drugs in First-Line Treatment of Small Cell Lung Cancer

  AUTHORS: Ying Wang, Xi Tang

  KEYWORDS: Anti-Angiogenesis, Small Cell Lung Cancer

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.1, January 12, 2023

  ABSTRACT: Small Cell Lung Cancer (SCLC) is a low-differentiated neuroendocrine tumor with rapid growth, early metastasis and sensitivity to radiotherapy and chemotherapy. It is highly recurrence rate. And there is lacking effective treatment now. As an active research direction at present, anti-angiogenic drugs are not only widely used in non-small cell lung cancer and other tumors, but also have certain effects in small cell lung cancer combined with chemotherapy. As one of the effective treatment methods for small cell lung cancer, related research is not rare, but there is still inadequacy, such as side effects can not be tolerated, and the timing of treatment can not be accurately assessed. This article will briefly describe the research progress of anti-angiogenic drugs combined with chemotherapy in the first-line treatment of extensive small cell lung cancer.